What is the primary immunological mechanism leading to villus atrophy in celiac disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The primary immunological mechanism leading to villus atrophy in celiac disease is an autoimmune reaction involving type 2 transglutaminase (TG2), triggered by gluten peptides in genetically susceptible individuals, particularly those with HLA-DQ2 or HLA-DQ8 molecules. This reaction is characterized by the deamidation of gliadin fractions, which increases their immunogenicity and facilitates binding to HLA-DQ2 or HLA-DQ8 molecules, leading to the activation of CD4+ T cells and the release of pro-inflammatory cytokines 1. The resulting inflammation and tissue injury cause crypt hyperplasia and villous atrophy, which are hallmark features of celiac disease. Key steps in this process include:

  • The ingestion of gluten, which is partially digested into peptides that cross the intestinal epithelium
  • The deamidation of these peptides by tissue transglutaminase (tTG), which increases their binding affinity to HLA-DQ2 or HLA-DQ8 molecules
  • The activation of CD4+ T cells, which release pro-inflammatory cytokines, such as interferon-gamma
  • The stimulation of matrix metalloproteinases and other enzymes that damage the intestinal epithelium
  • The activation of intraepithelial lymphocytes, which directly kill enterocytes through various mechanisms. The evidence from the study published in Nature Reviews Gastroenterology and Hepatology in 2024 1 supports this mechanism, highlighting the importance of gluten avoidance in managing celiac disease.

From the Research

Primary Immunological Mechanism Leading to Villus Atrophy in Celiac Disease

The primary immunological mechanism leading to villus atrophy in celiac disease involves:

  • Activation of gluten-specific CD4+ T cells expressing T cell receptors that recognize gluten peptides presented in the context of HLA-DQ2 and DQ8 2
  • Binding of gluten peptides to HLA-DQ2 and/or DQ8 molecules on antigen-presenting cells, which triggers a T cell-driven small intestinal inflammation 3, 4
  • Modification of gluten peptides by tissue transglutaminase (tTG), which enhances their immunostimulatory effect and leads to the activation of gluten-reactive T cells 4
  • Release of tTG from cells during inflammation, which also serves as a target autoantigen in the immune response 4

Key Factors Involved in the Immunological Mechanism

  • HLA-DQ2 and/or DQ8 haplotype, which is expressed by genetically susceptible individuals 3, 4, 5
  • Gluten peptides, which are efficiently presented by celiac disease-specific HLA-DQ2- and HLA-DQ8-positive antigen-presenting cells to CD4(+) T-cells 4
  • Tissue transglutaminase (tTG), which plays a crucial role in the pathogenesis of celiac disease by modifying gluten peptides and serving as a target autoantigen 4, 5

Consequences of the Immunological Mechanism

  • Villous atrophy, crypt hyperplasia, and intraepithelial lymphocytosis, which are the histological hallmarks of celiac disease 3, 4
  • Malabsorption of nutrients, including iron, which can lead to anemia and other complications 6
  • Increased risk of autoimmune diseases, osteoporosis, and intestinal T cell lymphoma in untreated celiac disease 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.